EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Opiranserin injection (Unafra®) as a first-in-class, non-opioid analgesic for the treatment of acute postoperative pain

Sang-Wook Lee, Inkyung Song, Jina Kim, Ji-Yeon Sim

Anesthesia and Pain Medicine · 31.10.2025 · 20 (4) · 309-317

DOI: 10.17085/apm.25369 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Anesthesia and Pain Medicine, erschienen am 31.10.2025. Verfasst von Sang-Wook Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Vivozon, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Opiranserin injection (Unafra®, Vivozon Inc.) is a first-in-class, non-opioid analgesic for the management of moderate-to-severe postoperative pain. The active ingredient, opiranserin (code name: VVZ-149), is a synthetic molecule that simultaneously antagonizes glycine transporter 2 (GlyT2) and serotonin 2A receptors (5-HT2A), both of which play key roles in pain processing. Opiranserin exemplifies the application of ex vivo phenotypic screening combined with a bait–target approach to identify effective multi-target agents that overcome the limitations of conventional single-target analgesics. In this review, we aim to describe the discovery and optimization of opiranserin through efficacy-based screening using a bait-target approach, outline its pharmacological mechanisms of action as a drug with both central and peripheral activity, and summarize published clinical studies demonstrating its successful translation from preclinical efficacy to reductions in postoperative pain and opioid consumption. We also discuss the clinical implications and future research directions to enhance the therapeutic utility of opiranserin injection and maximize patient benefit within the framework of precision analgesia.

Schlagwörter

Stichwörter der Autor:innen

Analgesics, non-narcoticGlycine plasma membrane transport proteinsMulti-target action drugPain, postoperativeReceptors, serotonin, 5-HT2Unafra

Autor:innen und Institutionen

  • Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Department of Global Research and Development, Vivozon, Inc., Princeton, NJ, USA.
  • Department of New Drug Development, Vivozon Inc., Seoul, Korea.

Förderung

  • Vivozon, Inc.

Zitieren

APA

Lee, S. W., Song, I., Kim, J., & Sim, J. Y. (2025). Opiranserin injection (Unafra®) as a first-in-class, non-opioid analgesic for the treatment of acute postoperative pain. Anesthesia and Pain Medicine, 20(4), 309-317. https://doi.org/10.17085/apm.25369

Vancouver

Lee SW, Song I, Kim J, Sim JY. Opiranserin injection (Unafra®) as a first-in-class, non-opioid analgesic for the treatment of acute postoperative pain. Anesthesia and Pain Medicine. 2025;20(4):309-317. doi:10.17085/apm.25369

BibTeX
@article{Lee2025,
  author = {Lee, Sang-Wook and Song, Inkyung and Kim, Jina and Sim, Ji-Yeon},
  title = {Opiranserin injection (Unafra®) as a first-in-class, non-opioid analgesic for the treatment of acute postoperative pain},
  journal = {Anesthesia and Pain Medicine},
  year = {2025},
  volume = {20},
  number = {4},
  pages = {309--317},
  doi = {10.17085/apm.25369}
}
Kostenlos starten →